MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, T. J.
Right arrow Articles by Maines, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, T. J.
Right arrow Articles by Maines, M. D.

Bromobenzene-mediated alteration in activity and electrophoretic pattern of biliverdin reductase variants in rat kidney

TJ Huang and MD Maines

University of Rochester School of Medicine, Department of Biophysics, New York 14642.

Here we report on the detection of multiple net-charge and molecular mass variants of biliverdin reductase in the rat kidney and describe selective changes in the tissue profile of the variants after bromobenzene treatment (2 mmol/kg, subcutaneously, 24 hr). Using two- dimensional electrophoresis and isoelectric focusing, two major molecular mass species, Mr 30,400 and 30,700, a minor form of Mr 31,400, and five net-charge groups of pI = 6.23, 5.91, 5.77, 5.61, and 5.48 were detected; the net-charge variants with pI = 5.61 and 5.77 were the most abundant forms. The Mr 30,400 form was the main component of two isoelectric focusing bands with pI = 6.23 and 5.91, and the relative amounts of these net-charge variants was severely decreased in the kidneys of bromobenzene-treated rats. The effect of bromobenzene in vivo could not be duplicated by in vitro experiments involving the direct treatment of purified enzyme with bromobenzene, or incubation of the purified preparation with bromobenzene in the presence of a NADPH- dependent microsomal drug-metabolizing system. Bromobenzene treatment did not alter the immunochemical properties of biliverdin reductase variants, as judged by the similarity of isoelectric focusing patterns of preparations on a Western blot using antibody raised against a rat liver total biliverdin reductase preparation. The treatment, however, caused an alteration in the kinetic properties of the enzyme, and the activity with NADH appeared to be selectively decreased. The possible mechanisms involved in the expression of multiple forms of the reductase and the biological significance of the multiplicity, as well as the change in composition caused by bromobenzene, are discussed.

Volume 37, Issue 1, pp. 25-29, 01/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. D. Maines, J. F. Ewing, T. J. Huang, and N. Panahian
Nuclear Localization of Biliverdin Reductase in the Rat Kidney: Response to Nephrotoxins That Induce Heme Oxygenase-1
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1091 - 1097.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics